See more : Glorywin Entertainment Group, Inc. (GWIN) Income Statement Analysis – Financial Results
Complete financial analysis of Rain Therapeutics Inc. (RAIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rain Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Valeura Energy Inc. (VLE.TO) Income Statement Analysis – Financial Results
- PT Sinar Mas Multiartha Tbk (SMMA.JK) Income Statement Analysis – Financial Results
- Tetra Bio-Pharma Inc. (TBPMF) Income Statement Analysis – Financial Results
- Aberdeen Diversified Income and Growth Trust plc (ADIG.L) Income Statement Analysis – Financial Results
- Scooters India Limited (SCOOTER.BO) Income Statement Analysis – Financial Results
Rain Therapeutics Inc. (RAIN)
About Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 61.40M | 40.77M | 15.37M | 7.29M |
| General & Administrative | 15.74M | 10.74M | 3.59M | 3.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.74M | 10.74M | 3.59M | 3.54M |
| Other Expenses | 0.00 | 1.00K | -2.02M | -251.00K |
| Operating Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Cost & Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Interest Income | 1.42M | 119.00K | 32.00K | 209.00K |
| Interest Expense | 0.00 | 0.00 | 135.00K | 32.00K |
| Depreciation & Amortization | 80.00K | 120.00K | -1.94M | -14.00K |
| EBITDA | -77.06M | -51.51M | -18.91M | -10.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -77.14M | -51.51M | -18.96M | -10.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 120.00K | -2.13M | -74.00K |
| Income Before Tax | -75.72M | -51.39M | -21.08M | -10.90M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.00K | 2.00K | -1.89M | -219.00K |
| Net Income | -75.72M | -51.39M | -19.20M | -10.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.71 | -2.65 | -1.80 | -1.00 |
| EPS Diluted | -2.71 | -2.65 | -1.80 | -1.00 |
| Weighted Avg Shares Out | 27.99M | 19.41M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 27.99M | 19.41M | 10.66M | 10.66M |
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Rain Oncology Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2023 - (NASDAQ: RAIN)
NEW YORK , Aug. 22, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rain Oncology Inc.. Shareholders who purchased shares of RAIN during the class period listed are encouraged to contact the firm regarding possible...
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RAIN
NEW YORK , Aug. 21, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and May 19, 2023, both dates inclusive (the "Class...
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit
LOS ANGELES , Aug. 21, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ:...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rain Oncology Inc. - RAIN
NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN). Such investors are advised to contact Robert S.
RAIN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Rain Oncology Inc.
NEW YORK, NY / ACCESSWIRE / August 18, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Rain Oncology Inc. ("Rain") (NASDAQ:RAIN) between July 20,...
RAIN LAWSUIT ALERT: Levi & Korsinsky Notifies Rain Oncology Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Aug. 17, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf...
RAIN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Rain Oncology Inc.
NEW YORK, NY / ACCESSWIRE / August 16, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Rain Oncology Inc. ("Rain") (NASDAQ:RAIN) between July 20,...
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit
LOS ANGELES , Aug. 16, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN)....
RAIN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 12, 2023 in the Class Action Filed on Behalf of Rain Oncology Inc. Shareholders
NEW YORK , Aug. 15, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Rain Oncology Inc. (NASDAQ: RAIN) alleging that the Company violated federal securities laws. Class...
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Rain Investors of a Lead Plaintiff Deadline of September 12, 2023
NEW YORK , Aug. 14, 2023 /PRNewswire/ -- Attention Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between July 20, 2021...
Source: https://incomestatements.info
Category: Stock Reports